Oxymetazoline
Identification
- Name
- Oxymetazoline
- Accession Number
- DB00935 (APRD01158)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
- Structure
- Synonyms
- 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
- 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
- 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
- 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
- Oximetazolinum
- Oxymetazolina
- Oxymetazoline
- Oxymétazoline
- Oxymetazolinum
- Oxymethazoline
- Oxymetozoline
- Product Ingredients
Ingredient UNII CAS InChI Key Oxymetazoline hydrochloride K89MJ0S5VY 2315-02-8 BEEDODBODQVSIM-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataRhofade Cream 1 g/100g Topical Aclaris Therapeutics, Inc. 2017-01-18 Not applicable US Rhofade Cream 10 mg/1g Topical Allergan, Inc. 2017-01-18 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional Data12 Hour Nasal Spray 0.05 g/100mL Nasal Select Brand Distributors 2000-03-01 2020-04-30 US 12 Hour Nasal Spray .05 g/100mL Nasal Meijer Distribution 2015-05-06 Not applicable US 12 Hour Nasal Spray 0.05 g/100mL Nasal Altaire Pharmaceuticals Inc. 2001-06-01 Not applicable US 12 Hour Nasal Spray 0.05 g/100mL Nasal Healthlife of Usa 2018-01-02 Not applicable US 12 Hour Original Nasal Decongestant Liquid 50 mg/100mL Nasal Preferred Pharmaceuticals Inc. 2018-01-02 Not applicable US 12 Hour Original Nasal Decongestant Liquid 50 mg/100mL Nasal Faria Llc Dba Sheffield Pharmaceutcials 2014-05-30 Not applicable US 7 Select Nasal Spray 0.05 g/100mL Nasal 7-Eleven 2014-08-05 2019-10-23 US 7 Select Original Nasal Spray 0.05 g/1mL Nasal 7-ELEVEN, INC. 2016-10-04 Not applicable US Aesb - Oxymetazoline Hydrochloride Nasal Solution USP, 0.025% Solution Nasal Bayer Not applicable Not applicable Canada Afrin Spray 0.5 mg/1mL Topical Navajo Manuracturing Company 2017-12-04 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Kovanaze Oxymetazoline hydrochloride (0.5 mg/1mL) + Tetracaine hydrochloride (30 mg/1mL) Spray Nasal St. Renatus 2016-09-01 Not applicable US - International/Other Brands
- Dristan 12-Hour / Duramist Plus / Genasal Nasal Spray Up to 12 Hour Relief / Iliadin / Neo-Synephrine 12 Hour Spray / Nezeril / Nostrilla 12 Hour Nasal Decongestant / OcuClear / Vicks Sinex 12 Hour Nasal Spray / Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief
- Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic alpha-1 Receptor Agonists
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Autonomic Agents
- Cardiovascular Agents
- Decongestants and Antiallergics
- Imidazoles
- Increased Sympathetic Activity
- Nasal Decongestants
- Nasal Preparations
- Neurotransmitter Agents
- Ophthalmologicals
- Peripheral Nervous System Agents
- Respiratory System Agents
- Sensory Organs
- Sympathomimetics
- Sympathomimetics Used as Decongestants
- Sympathomimetics, Plain
- Vasoconstriction
- Vasoconstrictor Agents
- UNII
- 8VLN5B44ZY
- CAS number
- 1491-59-4
- Weight
- Average: 260.3746
Monoisotopic: 260.1888634 - Chemical Formula
- C16H24N2O
- InChI Key
- WYWIFABBXFUGLM-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)
- IUPAC Name
- 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
- SMILES
- CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
Pharmacology
- Indication
For treatment of nasal congestion and redness associated with minor irritations of the eye
- Associated Conditions
- Pharmacodynamics
Oxymetazoline a adrenergic alpha-agonists, direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis.
- Mechanism of action
Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion.
Target Actions Organism AAlpha-1A adrenergic receptor agonistHumans AAlpha-2A adrenergic receptor agonistpartial agonistHumans UAlpha-2C adrenergic receptor agonistHumans UAlpha-2B adrenergic receptor binderHumans UAlpha-1B adrenergic receptor agonistHumans UAlpha-1D adrenergic receptor agonistHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.
Learn moreStructured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.
Learn moreStructured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.
Learn moreInteractions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional Data1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of hypertension can be increased when Oxymetazoline is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid. 1-benzylimidazole The risk or severity of hypertension can be increased when Oxymetazoline is combined with 1-benzylimidazole. 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 2,5-Dimethoxy-4-ethylamphetamine. 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. 3-isobutyl-1-methyl-7H-xanthine The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3-isobutyl-1-methyl-7H-xanthine. 3,5-diiodothyropropionic acid The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3,5-diiodothyropropionic acid. 3,5-Diiodotyrosine The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3,5-Diiodotyrosine. 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 4-Bromo-2,5-dimethoxyamphetamine. 4-Methoxyamphetamine The risk or severity of hypertension can be increased when Oxymetazoline is combined with 4-Methoxyamphetamine. 5-methoxy-N,N-dimethyltryptamine The risk or severity of hypertension can be increased when Oxymetazoline is combined with 5-methoxy-N,N-dimethyltryptamine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015070
- KEGG Compound
- C07363
- PubChem Compound
- 4636
- PubChem Substance
- 46505622
- ChemSpider
- 4475
- BindingDB
- 30712
- ChEBI
- 7862
- ChEMBL
- CHEMBL762
- Therapeutic Targets Database
- DAP000235
- PharmGKB
- PA164748840
- Guide to Pharmacology
- GtP Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Oxymetazoline
- ATC Codes
- S01GA04 — Oxymetazoline
- S01GA — Sympathomimetics used as decongestants
- S01G — DECONGESTANTS AND ANTIALLERGICS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- R01AB — Sympathomimetics, combinations excl. corticosteroids
- R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
- R01 — NASAL PREPARATIONS
- R — RESPIRATORY SYSTEM
- AHFS Codes
- 52:32.00 — Vasoconstrictors
- MSDS
- Download (74.6 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Schering plough healthcare products inc
- Johnson and johnson group consumer companies
- Packagers
- Altaire Pharmaceuticals
- Bayer Healthcare
- Chain Drug
- CVS Pharmacy
- Palmetto Pharmaceuticals Inc.
- Perrigo Co.
- Pfizer Inc.
- S&P Healthcare
- Spectrum Pharmaceuticals
- Target Corp.
- Walgreen Co.
- Wyeth Pharmaceuticals
- Dosage forms
Form Route Strength Liquid Nasal 50 mg/100mL Spray Topical 0.5 mg/1mL Spray, metered Nasal 0.05 g/100mL Spray, metered Nasal 0.05 mg/1mL Spray Nasal 0.05 mg/100mL Spray Nasal 0.2 mg/0.4mL Spray Nasal 0.05 g/1mL Spray Nasal 0.00050 g/1mL Spray Nasal Spray Nasal 0.05 mg/100mg Liquid Nasal Spray Nasal Solution Nasal 0.05 g/100mL Solution Nasal 0.05 mg/100mL Solution / drops; spray Nasal Kit 0.05 g/100mL Spray Nasal 5 g/100mL Solution / drops Nasal 0.05 g/100mL Liquid Topical 0.05 g/100mL Spray Nasal 0.05 mg/1mL Spray, metered Nasal 0.0005 mL/100mL Spray, metered Nasal 0.05 mg/100mL Solution / drops Ophthalmic Spray, metered Nasal Spray Oral 0.5 mg/1mL Spray, metered Nasal 0.2 mg/0.4mL Spray, metered Nasal 0.5 mg/1mL Spray Nasal 0.05 mg/1 Spray Nasal 50.0 mg/100.0mL Spray Nasal 50 mg/100mL Cream Topical 1 g/100g Cream Topical 10 mg/1g Spray Nasal 7.5 mg/15mL Spray Nasal 0.5 mg/1mL Spray Nasal 0.05 g/100mL Spray Nasal 0.512 mg/1mL Spray Nasal 0.0005 g/1mL Spray Nasal 0.0005055 g/1mL Spray Nasal 0.0005095 g/1mL Spray Nasal 0.000512 g/1mL Liquid Ophthalmic 0.25 mg/1mL Liquid Ophthalmic Spray Nasal .005 g/100mL Spray Nasal .05 g/100mL Spray Nasal .5 mg/1mL Solution Nasal - Prices
Unit description Cost Unit Oxymetazoline hcl powder 84.42USD g Afrin 0.05% nose spray 0.62USD ml Drixoral cold & allergy tablet sa 0.4USD tablet Afrin no drip sinus pump mist 0.38USD ml Oxymetazoline 0.05% spray 0.38USD ml Anefrin 0.05% nasal spray 0.37USD ml Afrin sinus spray 0.33USD ml Dristan long lasting mist 0.32USD ml Neo-synephrine 12 hour spray 0.28USD ml Visine long lasting eye drops 0.27USD ml 12 hour nasal relief spray 0.24USD ml Dristan cold multi-symp tablet 0.23USD tablet Ocuclear eye drops 0.23USD ml CVS Pharmacy nasal spray 0.05% 0.22USD ml No drip 0.05% nasal spray 0.13USD ml Nasal spray 0.05% 0.06USD ml Sinus nasal spray 0.06USD ml Nasal decongestant 0.05% spray 0.03USD ml Pv nasal spray 0.05% 0.03USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Unlock Additional DataUS8580282 No 2013-11-12 2030-04-02 US US6413499 No 2002-07-02 2020-03-20 US US9308191 No 2016-04-12 2030-04-02 US US8883838 No 2014-11-11 2031-12-01 US US7812049 No 2010-10-12 2028-05-02 US US8420688 No 2013-04-16 2024-08-02 US US9974773 No 2018-05-22 2035-06-11 US US8815929 No 2014-08-26 2024-01-22 US US10335391 No 2015-06-11 2035-06-11 US Additional Data Available- Filed On
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 182 °C PhysProp logP 3.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0515 mg/mL ALOGPS logP 3.7 ALOGPS logP 3.03 ChemAxon logS -3.7 ALOGPS pKa (Strongest Acidic) 10.91 ChemAxon pKa (Strongest Basic) 10.15 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 44.62 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 79.8 m3·mol-1 ChemAxon Polarizability 30.64 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9761 Blood Brain Barrier - 0.5388 Caco-2 permeable - 0.567 P-glycoprotein substrate Substrate 0.8858 P-glycoprotein inhibitor I Non-inhibitor 0.9477 P-glycoprotein inhibitor II Non-inhibitor 0.6585 Renal organic cation transporter Inhibitor 0.6039 CYP450 2C9 substrate Non-substrate 0.7585 CYP450 2D6 substrate Non-substrate 0.5707 CYP450 3A4 substrate Non-substrate 0.5394 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Inhibitor 0.8931 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.854 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8682 Ames test Non AMES toxic 0.7951 Carcinogenicity Non-carcinogens 0.8923 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 4.4155 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8402 hERG inhibition (predictor II) Non-inhibitor 0.7432
Spectra
- Mass Spec (NIST)
- Download (10.5 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as xylenols. These are aromatic compounds that contain a xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups, and at least one hydroxyl group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Xylenes
- Direct Parent
- Xylenols
- Alternative Parents
- Phenylpropanes / m-Xylenes / Para cresols / Ortho cresols / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds show 3 more
- Substituents
- Xylenol / Phenylpropane / M-xylene / O-cresol / P-cresol / Phenol / Imidolactam / 2-imidazoline / Amidine / Carboxylic acid amidine show 12 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- phenols, carboxamidine, imidazolines (CHEBI:7862)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1A
- Uniprot ID
- P35348
- Uniprot Name
- Alpha-1A adrenergic receptor
- Molecular Weight
- 51486.005 Da
References
- Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91. [PubMed:8894610]
- Deplanne V, Galzin AM: Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. J Pharmacol Exp Ther. 1996 Aug;278(2):527-34. [PubMed:8768700]
- Shibata K, Taketani K: [Excitatory effect of noradrenaline on rat airway parasympathetic ganglion neurons]. Fukuoka Igaku Zasshi. 2001 Nov;92(11):377-83. [PubMed:11774707]
- Furukawa K, Rosario DJ, Smith DJ, Chapple CR, Uchiyama T, Chess-Williams R: Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol. 1995 Sep;116(1):1605-10. [PubMed:8564226]
- Gonzalez-Espinosa C, Romero-Avila MT, Mora-Rodriguez DM, Gonzalez-Espinosa D, Garcia-Sainz JA: Molecular cloning and functional expression of the guinea pig alpha(1a)-adrenoceptor. Eur J Pharmacol. 2001 Aug 31;426(3):147-55. [PubMed:11527538]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- AgonistPartial agonist
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
- Gene Name
- ADRA2A
- Uniprot ID
- P08913
- Uniprot Name
- Alpha-2A adrenergic receptor
- Molecular Weight
- 48956.275 Da
References
- MacKinnon AC, Kilpatrick AT, Kenny BA, Spedding M, Brown CM: [3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification. Br J Pharmacol. 1992 Aug;106(4):1011-8. [PubMed:1327384]
- Mitrani P, Srinivasan M, Dodds C, Patel MS: Role of the autonomic nervous system in the development of hyperinsulinemia by high-carbohydrate formula feeding to neonatal rats. Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1069-78. Epub 2006 Dec 12. [PubMed:17164433]
- Lepretre N, Mironneau J: Alpha 2-adrenoceptors activate dihydropyridine-sensitive calcium channels via Gi-proteins and protein kinase C in rat portal vein myocytes. Pflugers Arch. 1994 Dec;429(2):253-61. [PubMed:7892112]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
- Gene Name
- ADRA2C
- Uniprot ID
- P18825
- Uniprot Name
- Alpha-2C adrenergic receptor
- Molecular Weight
- 49521.585 Da
References
- Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Epinephrine binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
- Gene Name
- ADRA2B
- Uniprot ID
- P18089
- Uniprot Name
- Alpha-2B adrenergic receptor
- Molecular Weight
- 49565.8 Da
References
- Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366]
- Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1B
- Uniprot ID
- P35368
- Uniprot Name
- Alpha-1B adrenergic receptor
- Molecular Weight
- 56835.375 Da
References
- Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
- Akinaga J, Lima V, Kiguti LR, Hebeler-Barbosa F, Alcantara-Hernandez R, Garcia-Sainz JA, Pupo AS: Differential phosphorylation, desensitization, and internalization of alpha1A-adrenoceptors activated by norepinephrine and oxymetazoline. Mol Pharmacol. 2013 Apr;83(4):870-81. doi: 10.1124/mol.112.082313. Epub 2013 Jan 30. [PubMed:23364786]
- Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Alpha1-adrenergic receptor activity
- Specific Function
- This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
- Gene Name
- ADRA1D
- Uniprot ID
- P25100
- Uniprot Name
- Alpha-1D adrenergic receptor
- Molecular Weight
- 60462.205 Da
References
- Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
- Akinaga J, Lima V, Kiguti LR, Hebeler-Barbosa F, Alcantara-Hernandez R, Garcia-Sainz JA, Pupo AS: Differential phosphorylation, desensitization, and internalization of alpha1A-adrenoceptors activated by norepinephrine and oxymetazoline. Mol Pharmacol. 2013 Apr;83(4):870-81. doi: 10.1124/mol.112.082313. Epub 2013 Jan 30. [PubMed:23364786]
- Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]
Drug created on June 13, 2005 07:24 / Updated on December 05, 2019 06:05